Total Payments
$1.1M
2024 Payments
$190,159
Companies
77
Transactions
2,592
Medicare Patients
6,245
Medicare Billing
$936,890
Payment Breakdown by Category
Other$599,469 (54.2%)
Research$373,808 (33.8%)
Travel$59,896 (5.4%)
Food & Beverage$53,953 (4.9%)
Consulting$19,089 (1.7%)
Gifts$136.80 (0.0%)
Education$56.47 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $599,469 | 403 | 54.2% |
| Unspecified | $373,808 | 67 | 33.8% |
| Travel and Lodging | $59,896 | 206 | 5.4% |
| Food and Beverage | $53,953 | 1,892 | 4.9% |
| Consulting Fee | $19,089 | 13 | 1.7% |
| Gift | $136.80 | 3 | 0.0% |
| Education | $56.47 | 8 | 0.0% |
Payments by Type
General
$732,599
2,525 transactions
Research
$373,808
67 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $390,428 | 111 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $263,205 | 458 | $0 (2024) |
| Lilly USA, LLC | $208,143 | 392 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $79,152 | 198 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $38,590 | 123 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $36,389 | 130 | $0 (2020) |
| Amgen Inc. | $16,476 | 105 | $0 (2024) |
| Senseonics, Incorporated | $14,025 | 11 | $0 (2019) |
| MannKind Corporation | $12,414 | 136 | $0 (2023) |
| ABBVIE INC. | $10,425 | 77 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $190,159 | 234 | Eli Lilly and Company ($107,465) |
| 2023 | $71,875 | 197 | Lilly USA, LLC ($48,518) |
| 2022 | $159,738 | 272 | Eli Lilly and Company ($76,477) |
| 2021 | $42,414 | 219 | Eli Lilly and Company ($19,560) |
| 2020 | $46,599 | 269 | Eli Lilly and Company ($18,145) |
| 2019 | $126,287 | 420 | AstraZeneca Pharmaceuticals LP ($53,744) |
| 2018 | $264,452 | 496 | AstraZeneca Pharmaceuticals LP ($107,382) |
| 2017 | $204,883 | 485 | AstraZeneca Pharmaceuticals LP ($68,203) |
All Payment Transactions
2,592 individual payment records from CMS Open Payments — Page 1 of 104
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 12/20/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Diabetes | ||||||
| 12/19/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: Diabetes Care | ||||||
| 12/12/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $11.02 | General |
| Category: Endocrinology | ||||||
| 12/11/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 12/09/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Diabetes | ||||||
| 12/06/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $13.52 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 12/05/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Diabetes | ||||||
| 12/04/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: Endocrinology | ||||||
| 11/21/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $24.31 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $77.34 | General |
| Category: Endocrinology | ||||||
| 11/19/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: Diabetes | ||||||
| 11/18/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Diabetes | ||||||
| 11/18/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: Diabetes | ||||||
| 11/14/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Diabetes | ||||||
| 11/07/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $114.07 | General |
| Category: Obesity | ||||||
| 10/29/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), SYNJARDY | Food and Beverage | In-kind items and services | $15.71 | General |
| Category: DIABETES | ||||||
| 10/29/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $13.70 | General |
| Category: Bone Health | ||||||
| 10/21/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: Diabetes Care | ||||||
| 10/17/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| 10/15/2024 | ABBVIE INC. | SYNTHROID (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly and Company | $58,933 | 4 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3298176 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $33,018 | 3 |
| A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $31,446 | 1 |
| A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | Eli Lilly and Company | $28,816 | 1 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) | Eli Lilly and Company | $28,249 | 1 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO, BOTH IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC IN ADULTS WITH TYPE 2 DIABETES PRONTO-T2D | Eli Lilly and Company | $27,477 | 3 |
| A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | Eli Lilly and Company | $19,411 | 1 |
| A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS | Eli Lilly and Company | $17,208 | 1 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $16,488 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $14,632 | 3 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-MONTH TRIAL OF LY3298176 VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $13,518 | 3 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) | Eli Lilly and Company | $9,705 | 1 |
| A PHASE 2 STUDY OF ONCE-DAILY LY3502970 COMPARED WITH PLACEBO AND ONCE-WEEKLY DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $8,147 | 2 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, 18-WEEK TRIAL OF INVESTIGATIONAL DULAGLUTIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES ON METFORMIN MONOTHERAPY | Eli Lilly and Company | $7,957 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | Eli Lilly and Company | $7,783 | 1 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | Eli Lilly and Company | $6,720 | 2 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $6,024 | 2 |
| A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | Eli Lilly and Company | $5,469 | 3 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $4,561 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | Eli Lilly and Company | $4,307 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $4,065 | 3 |
| A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | Eli Lilly and Company | $3,799 | 2 |
| A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $3,747 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF THREE TIRZEPATIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES, INADEQUATELY CONTROLLED WITH DIET AND EXERCISE ALONE | Eli Lilly and Company | $2,882 | 2 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $2,666 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK | Regeneron Pharmaceuticals, Inc. | $1,972 | 9 |
| A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | Eli Lilly and Company | $1,761 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | Eli Lilly and Company | $1,553 | 2 |
| A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | Eli Lilly and Company | $620.01 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $366.67 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | Eli Lilly and Company | $298.02 | 1 |
| A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $142.50 | 1 |
| NN9535-4352 | Novo Nordisk Inc | $48.00 | 1 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $19.10 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,632 | 3,246 | $597,513 | $246,406 |
| 2022 | 11 | 1,595 | 3,163 | $597,462 | $253,684 |
| 2021 | 10 | 1,348 | 2,810 | $534,627 | $224,892 |
| 2020 | 12 | 1,670 | 3,028 | $578,855 | $211,908 |
Total Patients
6,245
Total Services
12,247
Medicare Billing
$936,890
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 730 | 2,043 | $434,260 | $184,090 | 42.4% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 171 | 173 | $38,375 | $13,720 | 35.8% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 223 | 474 | $33,654 | $12,545 | 37.3% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2023 | 90 | 92 | $26,459 | $9,787 | 37.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 134 | 138 | $19,999 | $8,814 | 44.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 81 | 103 | $9,023 | $4,335 | 48.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $10,617 | $4,068 | 38.3% |
| 95923 | Testing of autonomic (sympathetic) nervous system function | Office | 2023 | 38 | 39 | $9,731 | $3,724 | 38.3% |
| 95921 | Testing of autonomic nervous system function and heart rate response to deep breathing | Office | 2023 | 38 | 39 | $6,359 | $2,652 | 41.7% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 68 | 86 | $6,482 | $1,946 | 30.0% |
| 92250 | Photography of the retina | Office | 2023 | 26 | 26 | $2,555 | $723.75 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 715 | 2,001 | $425,333 | $186,874 | 43.9% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 183 | 185 | $41,037 | $13,873 | 33.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 158 | 179 | $25,941 | $11,814 | 45.5% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 186 | 426 | $30,246 | $11,569 | 38.3% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2022 | 72 | 81 | $23,296 | $9,289 | 39.9% |
| 95923 | Testing of autonomic (sympathetic) nervous system function | Office | 2022 | 60 | 64 | $15,968 | $6,120 | 38.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 47 | 47 | $15,122 | $5,891 | 39.0% |
| 95921 | Testing of autonomic nervous system function and heart rate response to deep breathing | Office | 2022 | 60 | 64 | $10,436 | $4,482 | 42.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 46 | 48 | $4,205 | $1,985 | 47.2% |
| 92250 | Photography of the retina | Office | 2022 | 33 | 33 | $3,243 | $965.89 | 29.8% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 35 | 35 | $2,638 | $821.15 | 31.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 695 | 1,894 | $402,589 | $174,576 | 43.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 130 | 150 | $21,738 | $9,685 | 44.6% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 140 | 366 | $25,986 | $9,624 | 37.0% |
About Dr. Michelle Welch, MD
Dr. Michelle Welch, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Shavano Park, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891764957.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michelle Welch, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $190,159 received in 2024. These payments were reported across 2,592 transactions from 77 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($599,469).
As a Medicare-enrolled provider, Welch has provided services to 6,245 Medicare beneficiaries, totaling 12,247 services with total Medicare billing of $936,890. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Shavano Park, TX
- Active Since 03/14/2006
- Last Updated 03/21/2017
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1891764957
Products in Payments
- FARXIGA (Drug) $213,629
- MOUNJARO (Drug) $160,912
- JARDIANCE (Drug) $68,078
- BYDUREON (Drug) $46,959
- SOLIQUA (Drug) $46,561
- INVOKANA (Drug) $36,915
- TRULICITY (Drug) $24,108
- TOUJEO (Drug) $22,454
- Eversense (Device) $14,025
- AFREZZA (Drug) $12,414
- EVENITY (Biological) $11,851
- PRALUENT ALIROCUMAB INJECTION (Biological) $7,565
- SYNTHROID (Drug) $5,963
- FreeStyle Libre Pro (Device) $5,134
- SOLIQUA 100/33 (Drug) $5,094
- Prolia (Biological) $3,444
- CeQur Simplicity (Device) $2,839
- DISEASE STATE (Drug) $2,655
- Minimed 670G System (Device) $2,450
- Ozempic (Drug) $1,239
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Shavano Park
Dr. Daniel Katselnik, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $896,649
Endocrinology, Diabetes & Metabolism $896,649
Dorota Malinowski, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $25,549
Endocrinology, Diabetes & Metabolism $25,549
Fernando Reyes San Martin
Endocrinology, Diabetes & Metabolism
Endocrinology, Diabetes & Metabolism